ALAS2 Antibody (N-term) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | P22557 |
---|---|
Other Accession | NP_000023.2 |
Clone Names | 80722009 |
Gene ID | 212 |
---|---|
Other Names | 5-aminolevulinate synthase, erythroid-specific, mitochondrial, ALAS-E, 5-aminolevulinic acid synthase 2, Delta-ALA synthase 2, Delta-aminolevulinate synthase 2, ALAS2, ALASE, ASB |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | ALAS2 |
---|---|
Synonyms | ALASE, ASB |
Function | Catalyzes the pyridoxal 5'-phosphate (PLP)-dependent condensation of succinyl-CoA and glycine to form aminolevulinic acid (ALA), with CoA and CO2 as by-products (PubMed:14643893, PubMed:32499479, PubMed:21252495, PubMed:21653323, PubMed:21309041). Contributes significantly to heme formation during erythropoiesis (PubMed:2050125). |
Cellular Location | Mitochondrion inner membrane; Peripheral membrane protein. Note=Localizes to the matrix side of the mitochondrion inner membrane. |
Tissue Location | [Isoform 1]: Erythroid-specific. [Isoform 3]: Erythroid-specific. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
ALAS2 specifies an erythroid-specificmitochondrially located enzyme. The encoded protein catalyzes thefirst step in the heme biosynthetic pathway. Defects in this genecause X-linked pyridoxine-responsive sideroblastic anemia.
References
Bergmann, A.K., et al. Pediatr Blood Cancer 54(2):273-278(2010)Kaneko, K., et al. FEBS J. 276(5):1370-1382(2009)Whatley, S.D., et al. Am. J. Hum. Genet. 83(3):408-414(2008)Sussman, N.L., et al. Acta Haematol. 120(3):168-173(2008)Rabstein, S., et al. J. Toxicol. Environ. Health Part A 71 (11-12), 716-724 (2008) :
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.